Overview

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Status:
Completed

Trial end date:
2016-09-15

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for 24 weeks in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead sponsored study and did not achieve sustained virologic response (SVR).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir